Generic Ximino Availability

Last updated on Jun 11, 2025.

Ximino is a brand name of minocycline, approved by the FDA in the following formulation(s):

XIMINO (minocycline hydrochloride - capsule, extended release;oral)

• Manufacturer: JOURNEY
  Approval date: July 11, 2012
  Strength(s): EQ 45MG BASE (discontinued), EQ 67.5MG BASE (discontinued), EQ 90MG BASE (discontinued), EQ 112.5MG BASE (discontinued), EQ 135MG BASE (discontinued)

All of the above formulations have been discontinued.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Ximino. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• Minocycline oral dosage forms for the treatment of acne
  Patent 7,541,347
  Issued: June 2, 2009
  Inventor(s): Wortzman; Mitchell et al.
  Assignee(s): Medicis Pharmaceutical Coropration (Scottsdale, AZ)
  

  Minocycline oral dosage forms containing a controlled release carrier are useful for the treatment of acne.

  Patent expiration dates:

  • April 2, 2027
    
    ✓ 
    Patent use: TREATMENT OF INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS
• Minocycline oral dosage forms for the treatment of acne
  Patent 7,544,373
  Issued: June 9, 2009
  Inventor(s): Wortzman; Mitchell et al.
  Assignee(s): Medicis Pharmaceutical Corporation (Scottsdale, AZ)
  

  Minocycline oral dosage forms containing a controlled release carrier are useful for the treatment of acne.

  Patent expiration dates:

  • April 2, 2027
    
    ✓ 
    Drug product
• Minocycline oral dosage forms for the treatment of acne
  Patent 7,790,705
  Issued: September 7, 2010
  Inventor(s): Wortzman; Mitchell et al.
  Assignee(s): Medicis Pharmaceutical Corporation (Scottsdale, AZ)
  

  Minocycline oral dosage forms containing a controlled release carrier are useful for the treatment of acne.

  Patent expiration dates:

  • June 24, 2025
    
    ✓ 
    Patent use: TREATMENT OF ACNE
• Method for the treatment of acne
  Patent 7,919,483
  Issued: April 5, 2011
  Inventor(s): Wortzman; Mitchell et al.
  Assignee(s): Medicis Pharmaceutical Corporation (Scottsdale, AZ)
  

  A method for treatment of acne with tetracyclines is provided. A lower sustained dose and no loading dose is employed, with an optional once-a-day dosing regimen.

  Patent expiration dates:

  • March 7, 2027
    
    ✓ 
    Patent use: TREATMENT OF ACNE
• Minocycline oral dosage forms for the treatment of acne
  Patent 8,252,776
  Issued: August 28, 2012
  Inventor(s): Wortzman Mitchell & Plott R. Todd & Bhatia Kuljit & Patel Bhiku
  Assignee(s): Medicis Pharmaceutical Corporation
  

  Minocycline oral dosage forms containing a controlled release carrier are useful for the treatment of acne.

  Patent expiration dates:

  • June 24, 2025
    
    ✓ 
    Patent use: TREATMENT OF ACNE
• Minocycline oral dosage forms for the treatment of acne
  Patent 8,268,804
  Issued: September 18, 2012
  Inventor(s): Wortzman Mitchell & Plott R. Todd & Bhatia Kuljit & Patel Bhiku
  Assignee(s): Medicis Pharmaceutical Corporation
  

  Minocycline oral dosage forms containing a controlled release carrier are useful for the treatment of acne.

  Patent expiration dates:

  • June 24, 2025
    
    ✓ 
    Patent use: TREATMENT OF ACNE

Related/similar drugs

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer